24/7 Market News Snapshot 16 October, 2025 – Citius Oncology, Inc. Common Stock (NASDAQ:CTOR)

October 16, 2025

DENVER, Colo., 16 October, 2025 (www.247marketnews.com) – (NASDAQ:CTOR) are discussed in this article.
Citius Oncology, Inc. is experiencing a significant upswing in its stock performance, with recent trading opening at $1.785 and peaking at $2.095—representing an increase of over 21.80%. This surge follows a previous close at $1.720, indicating strong market momentum and heightened investor interest. The current trading volume of 683.46K reinforces the positive market sentiment, positioning Citius Oncology as a stock to observe closely as the company advances in cancer therapeutics.

In addition to market momentum, Citius Oncology recently solidified a pivotal exclusive agreement with EVERSANA® aimed at comprehensive commercialization services in anticipation of the U.S. launch of LYMPHIR™, an FDA-approved therapy targeting relapsed or refractory cutaneous T-cell lymphoma (CTCL). This collaboration marks a significant milestone as EVERSANA will provide essential operational services, including medical information management, pharmacovigilance, revenue cycle management, and data analytics. These efforts are intended to ensure a solid foundation for both pre-launch and post-launch phases, ultimately improving accessibility to this innovative treatment.

Leonard Mazur, Chairman and CEO of Citius Oncology, highlighted the importance of this partnership, noting that the collaboration with EVERSANA is instrumental for enhancing operational readiness as they prepare for the market introduction of LYMPHIR. He emphasized that EVERSANA’s extensive oncology expertise will mitigate execution risks and is poised to create long-term value for shareholders.

LYMPHIR aims to fill critical unmet needs in the treatment landscape for CTCL by targeting IL-2 receptors on malignant and regulatory T-cells. The anticipated market launch in the fourth quarter of 2025 reflects Citius Oncology’s commitment to providing transformative therapies for patients grappling with this challenging form of skin cancer, underscoring their dedication to improving patient outcomes in oncology.

Related news for (CTOR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.